Items where authors include "Franks, K."

Article

Kapadi, A., Price, G., Faivre-Finn, C. et al. (8 more authors) (2024) Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ views. BMJ Oncology, 3 (1). e000226. ISSN 2752-7948

Burnett, C. orcid.org/0000-0003-1406-0920, Bestall, J., Boland, A. et al. (10 more authors) (2024) The Prehabilitation Radiotherapy Exercise, smoking Habit cessation and Balanced diet Study (PREHABS) protocol to explore the feasibility of embedding behavioural modifications into the clinical pathway for patients undergoing radical radiotherapy for lung cancer. BMJ Open, 14 (1). e081365. ISSN 2044-6055

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Haslett, K., Bayman, N., Franks, K. et al. (10 more authors) (2021) Isotoxic intensity modulated radiation therapy in stage III non-small cell lung cancer: a feasibility study. International Journal of Radiation Oncology*Biology*Physics, 109 (5). pp. 1341-1348. ISSN 0360-3016

Haslett, K., Franks, K., Hanna, G.G. et al. (12 more authors) (2016) Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open, 6 (4). e010457. e010457-e010457. ISSN 2044-6055

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.

Haslett, K., Ashcroft, L., Bayman, N. et al. (11 more authors) (2018) PO-0752: Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S387-S387.

Haslett, K., Bayman, N., Franks, K. et al. (11 more authors) (2017) MA 09.11 Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) – a feasibility study. In: Journal of Thoracic Oncology. IASLC 18th World Conference on Lung Cancer, 15-18 Oct 2017, Yokohama, Japan. Elsevier , S1838-S1839.

Croudace, T., Brazier, J., Gutacker, N. et al. (55 more authors) (2016) Proceedings of Patient Reported Outcome Measure’s (PROMs) Conference Sheffield 2016: advances in patient reported outcomes research. In: Health and Quality of Life Outcomes. Patient Reported Outcome Measure’s (PROMs) Conference 2016, 09 Jun 2016, Sheffield, UK. BMC .